Record Information |
---|
Version | 5.0 |
---|
Status | Detected and Quantified |
---|
Creation Date | 2005-11-16 15:48:42 UTC |
---|
Update Date | 2023-02-21 17:15:05 UTC |
---|
HMDB ID | HMDB0000710 |
---|
Secondary Accession Numbers | - HMDB0015507
- HMDB00710
- HMDB15507
|
---|
Metabolite Identification |
---|
Common Name | 4-Hydroxybutyric acid |
---|
Description | 4-Hydroxybutyric acid (also known as gamma-hydroxybutyrate or GHB) is a precursor and a metabolite of gamma-aminobutyric acid (GABA). GHB acts as a central nervous system (CNS) neuromodulator, mediating its effects through GABA and GHB-specific receptors, or by affecting dopamine transmission (PMID: 16620539 ). GHB occurs naturally in all mammals, but its function remains unknown. GHB is labeled as an illegal drug in most countries, but it also is used as a legal drug (Xyrem) in patients with narcolepsy. It is used illegally (under the street names juice, liquid ecstasy, or G) as an intoxicant for increasing athletic performance and as a date rape drug. In high doses, GHB inhibits the CNS, inducing sleep and inhibiting the respiratory drive. In lower doses, its euphoriant effect predominates (PMID: 17658710 ). When present in sufficiently high levels, 4-hydroxybutyric acid can act as an acidogen, a neurotoxin, and a metabotoxin. An acidogen is an acidic compound that induces acidosis, which has multiple adverse effects on many organ systems. A neurotoxin is a compound that adversely affects neural cells and tissues. A metabotoxin is an endogenously produced metabolite that causes adverse health effects at chronically high levels. Chronically high levels of 4-hydroxybutyric acid are associated with two inborn errors of metabolism: glutaric aciduria II and succinic semialdehyde dehydrogenase deficiency (SSADH). SSADH deficiency leads to a 30-fold increase of GHB and a 2-4 fold increase of GABA in the brains of patients with SSADH deficiency as compared to normal brain concentrations of the compounds. As an acidogen, 4-hydroxybutyric acid is an organic acid, and abnormally high levels of organic acids in the blood (organic acidemia), urine (organic aciduria), the brain, and other tissues lead to general metabolic acidosis. Acidosis typically occurs when arterial pH falls below 7.35. In infants with acidosis, the initial symptoms include poor feeding, vomiting, loss of appetite, weak muscle tone (hypotonia), and lack of energy (lethargy). These can progress to heart abnormalities, kidney abnormalities, liver damage, seizures, coma, and possibly death. Many affected children with organic acidemias experience intellectual disability or delayed development. These are also the characteristic symptoms of the untreated IEMs mentioned above. Particularly for SSADH deficiency, the most common features observed include developmental delay, hypotonia, and intellectual disability. Nearly half of patients exhibit ataxia, seizures, behaviour problems, and hyporeflexia. In adults, acidosis or acidemia is characterized by headaches, confusion, feeling tired, tremors, sleepiness, and seizures. As a neurotoxin, GHB appears to affect both GABA (a neurotransmitter) signaling and glutamate signaling (another neurotransmitter). Glutamine metabolism may also play a role in the pathophysiology of excessive levels of GHB. High levels of GHB have been shown to depress both the NMDA and AMPA/kainite receptor-mediated functions and may also alter glutamatergic excitatory synaptic transmission as well. 4-Hydroxybutyric acid is a microbial metabolite found in Aeromonas, Escherichia and Pseudomonas (PMID: 19434404 ). |
---|
Structure | InChI=1S/C4H8O3/c5-3-1-2-4(6)7/h5H,1-3H2,(H,6,7) |
---|
Synonyms | Value | Source |
---|
3-Carboxypropoxy acid | ChEBI | 4-Hydroxy-butyric acid | ChEBI | 4-Hydroxyalkanoic acid | ChEBI | 4-Hydroxybutanoate | ChEBI | 4-Hydroxybutanoic acid | ChEBI | 4-Hydroxycarboxylic acid | ChEBI | Gamma Hydroxybutyric acid | ChEBI | gamma-Hydroxybutyric acid | ChEBI | GHB | ChEBI | Oxy-N-butyric acid | ChEBI | Xyrem | ChEBI | 4-Hydroxy-butyrate | Generator | 4-Hydroxyalkanoate | Generator | 4-Hydroxycarboxylate | Generator | g Hydroxybutyrate | Generator | g Hydroxybutyric acid | Generator | gamma Hydroxybutyrate | Generator | Γ hydroxybutyrate | Generator | Γ hydroxybutyric acid | Generator | g-Hydroxybutyrate | Generator | g-Hydroxybutyric acid | Generator | gamma-Hydroxybutyrate | Generator | Γ-hydroxybutyrate | Generator | Γ-hydroxybutyric acid | Generator | Oxy-N-butyrate | Generator | 4-Hydroxybutyrate | Generator | 4-Hydroxy-butanoate | HMDB | 4-Hydroxy-butanoic acid | HMDB | 4-Hydroxybutyrate sodium | HMDB | 4-Hydroxybutyric acid monosodium salt | HMDB | gamma-Hydroxy butyrate | HMDB | gamma-Hydroxy sodium butyrate | HMDB | gamma-Hydroxybutyrate sodium | HMDB | Hydroxybutyric acid | HMDB |
|
---|
Chemical Formula | C4H8O3 |
---|
Average Molecular Weight | 104.1045 |
---|
Monoisotopic Molecular Weight | 104.047344122 |
---|
IUPAC Name | 4-hydroxybutanoic acid |
---|
Traditional Name | gamma hydroxybutyric acid |
---|
CAS Registry Number | 591-81-1 |
---|
SMILES | OCCCC(O)=O |
---|
InChI Identifier | InChI=1S/C4H8O3/c5-3-1-2-4(6)7/h5H,1-3H2,(H,6,7) |
---|
InChI Key | SJZRECIVHVDYJC-UHFFFAOYSA-N |
---|
Chemical Taxonomy |
---|
Description | Belongs to the class of organic compounds known as hydroxy fatty acids. These are fatty acids in which the chain bears a hydroxyl group. |
---|
Kingdom | Organic compounds |
---|
Super Class | Lipids and lipid-like molecules |
---|
Class | Fatty Acyls |
---|
Sub Class | Fatty acids and conjugates |
---|
Direct Parent | Hydroxy fatty acids |
---|
Alternative Parents | |
---|
Substituents | - Short-chain hydroxy acid
- Hydroxy fatty acid
- Straight chain fatty acid
- Monocarboxylic acid or derivatives
- Carboxylic acid
- Carboxylic acid derivative
- Organic oxygen compound
- Organic oxide
- Hydrocarbon derivative
- Primary alcohol
- Organooxygen compound
- Carbonyl group
- Alcohol
- Aliphatic acyclic compound
|
---|
Molecular Framework | Aliphatic acyclic compounds |
---|
External Descriptors | |
---|
Ontology |
---|
Physiological effect | |
---|
Disposition | |
---|
Process | |
---|
Role | |
---|
Physical Properties |
---|
State | Solid |
---|
Experimental Molecular Properties | Property | Value | Reference |
---|
Melting Point | Not Available | Not Available | Boiling Point | Not Available | Not Available | Water Solubility | Not Available | Not Available | LogP | Not Available | Not Available |
|
---|
Experimental Chromatographic Properties | Not Available |
---|
Predicted Molecular Properties | |
---|
Predicted Chromatographic Properties | Predicted Collision Cross SectionsPredicted Kovats Retention IndicesUnderivatizedDerivatizedDerivative Name / Structure | SMILES | Kovats RI Value | Column Type | Reference |
---|
4-Hydroxybutyric acid,1TMS,isomer #1 | C[Si](C)(C)OCCCC(=O)O | 1183.8 | Semi standard non polar | 33892256 | 4-Hydroxybutyric acid,1TMS,isomer #2 | C[Si](C)(C)OC(=O)CCCO | 1120.8 | Semi standard non polar | 33892256 | 4-Hydroxybutyric acid,2TMS,isomer #1 | C[Si](C)(C)OCCCC(=O)O[Si](C)(C)C | 1244.9 | Semi standard non polar | 33892256 | 4-Hydroxybutyric acid,1TBDMS,isomer #1 | CC(C)(C)[Si](C)(C)OCCCC(=O)O | 1411.7 | Semi standard non polar | 33892256 | 4-Hydroxybutyric acid,1TBDMS,isomer #2 | CC(C)(C)[Si](C)(C)OC(=O)CCCO | 1346.7 | Semi standard non polar | 33892256 | 4-Hydroxybutyric acid,2TBDMS,isomer #1 | CC(C)(C)[Si](C)(C)OCCCC(=O)O[Si](C)(C)C(C)(C)C | 1680.0 | Semi standard non polar | 33892256 |
|
---|
Spectra |
---|
| GC-MS SpectraSpectrum Type | Description | Splash Key | Deposition Date | Source | View |
---|
Experimental GC-MS | GC-MS Spectrum - 4-Hydroxybutyric acid GC-MS (2 TMS) | splash10-0159-2920000000-131f94186a93d0aa315d | 2014-06-16 | HMDB team, MONA, MassBank | View Spectrum | Experimental GC-MS | GC-MS Spectrum - 4-Hydroxybutyric acid GC-MS (Non-derivatized) | splash10-0159-2920000000-131f94186a93d0aa315d | 2017-09-12 | HMDB team, MONA, MassBank | View Spectrum | Experimental GC-MS | GC-MS Spectrum - 4-Hydroxybutyric acid GC-EI-TOF (Non-derivatized) | splash10-0002-0910000000-7240955b6b16291cf793 | 2017-09-12 | HMDB team, MONA, MassBank | View Spectrum | Predicted GC-MS | Predicted GC-MS Spectrum - 4-Hydroxybutyric acid GC-MS (Non-derivatized) - 70eV, Positive | splash10-0a5c-9000000000-915d32c0dbd6e6d19a55 | 2017-09-01 | Wishart Lab | View Spectrum | Predicted GC-MS | Predicted GC-MS Spectrum - 4-Hydroxybutyric acid GC-MS (2 TMS) - 70eV, Positive | splash10-00di-9610000000-52e5254f6eba257ad184 | 2017-10-06 | Wishart Lab | View Spectrum | Predicted GC-MS | Predicted GC-MS Spectrum - 4-Hydroxybutyric acid GC-MS (Non-derivatized) - 70eV, Positive | Not Available | 2021-10-12 | Wishart Lab | View Spectrum | Predicted GC-MS | Predicted GC-MS Spectrum - 4-Hydroxybutyric acid GC-MS (Non-derivatized) - 70eV, Positive | Not Available | 2021-10-12 | Wishart Lab | View Spectrum | Predicted GC-MS | Predicted GC-MS Spectrum - 4-Hydroxybutyric acid GC-MS (TMS_1_1) - 70eV, Positive | Not Available | 2021-11-05 | Wishart Lab | View Spectrum | Predicted GC-MS | Predicted GC-MS Spectrum - 4-Hydroxybutyric acid GC-MS (TMS_1_2) - 70eV, Positive | Not Available | 2021-11-05 | Wishart Lab | View Spectrum | Predicted GC-MS | Predicted GC-MS Spectrum - 4-Hydroxybutyric acid GC-MS (TBDMS_1_1) - 70eV, Positive | Not Available | 2021-11-05 | Wishart Lab | View Spectrum | Predicted GC-MS | Predicted GC-MS Spectrum - 4-Hydroxybutyric acid GC-MS (TBDMS_1_2) - 70eV, Positive | Not Available | 2021-11-05 | Wishart Lab | View Spectrum | Predicted GC-MS | Predicted GC-MS Spectrum - 4-Hydroxybutyric acid GC-MS (TBDMS_2_1) - 70eV, Positive | Not Available | 2021-11-05 | Wishart Lab | View Spectrum | MS | Mass Spectrum (Electron Ionization) | splash10-0006-9000000000-d55d971a361b41564681 | 2014-09-20 | Not Available | View Spectrum |
MS/MS SpectraSpectrum Type | Description | Splash Key | Deposition Date | Source | View |
---|
Experimental LC-MS/MS | LC-MS/MS Spectrum - 4-Hydroxybutyric acid QqQ 10V, positive-QTOF | splash10-14ii-9400000000-77378d9d837f1823ed37 | 2020-07-21 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - 4-Hydroxybutyric acid Orbitrap 0V, negative-QTOF | splash10-0udi-0900000000-ca02549abb7c7402b481 | 2020-07-22 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - 4-Hydroxybutyric acid Orbitrap 1V, negative-QTOF | splash10-0udi-0900000000-942af3cd327a2dd39887 | 2020-07-22 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - 4-Hydroxybutyric acid Orbitrap 1V, negative-QTOF | splash10-0udi-1900000000-671c45f3bda2eabba3c1 | 2020-07-22 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - 4-Hydroxybutyric acid Orbitrap 1V, negative-QTOF | splash10-0udi-1900000000-36fabc35679210a4621a | 2020-07-22 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - 4-Hydroxybutyric acid Orbitrap 1V, negative-QTOF | splash10-0udi-2900000000-146b4ca6698f6c40d476 | 2020-07-22 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - 4-Hydroxybutyric acid Orbitrap 2V, negative-QTOF | splash10-0udi-4900000000-32e86ae76401d830a8a1 | 2020-07-22 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - 4-Hydroxybutyric acid Orbitrap 2V, negative-QTOF | splash10-0udi-8900000000-07fc17585cf5e8d2ba9b | 2020-07-22 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - 4-Hydroxybutyric acid Orbitrap 3V, negative-QTOF | splash10-0pbi-9400000000-70777a3c6521e72b59b4 | 2020-07-22 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - 4-Hydroxybutyric acid n/a 7V, negative-QTOF | splash10-0a4i-9000000000-cad0cc415c906a783cfc | 2020-07-22 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - 4-Hydroxybutyric acid Orbitrap 3V, negative-QTOF | splash10-0zg0-9500000000-9dfcd62aeff3ff1e731d | 2020-07-22 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - 4-Hydroxybutyric acid Orbitrap 3V, negative-QTOF | splash10-0pb9-9300000000-0e1b3056ef85c0fbe59d | 2020-07-22 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - 4-Hydroxybutyric acid Orbitrap 3V, negative-QTOF | splash10-0a4i-9200000000-144d4f05dfc0b2dbd827 | 2020-07-22 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - 4-Hydroxybutyric acid Orbitrap 4V, negative-QTOF | splash10-0a4i-9100000000-5a807248d180fcc738ee | 2020-07-22 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - 4-Hydroxybutyric acid Orbitrap 5V, negative-QTOF | splash10-0a4i-9000000000-aeb70e18a8467ef1b4b1 | 2020-07-22 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - 4-Hydroxybutyric acid Orbitrap 5V, negative-QTOF | splash10-0a4i-9000000000-50691ede3dffed6a4afb | 2020-07-22 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - 4-Hydroxybutyric acid Orbitrap 6V, negative-QTOF | splash10-0a4i-9000000000-13adfaf490932a7c0fb9 | 2020-07-22 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - 4-Hydroxybutyric acid n/a 7V, negative-QTOF | splash10-000i-9000000000-3051dc4fe82b4abf5478 | 2020-07-22 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - 4-Hydroxybutyric acid Orbitrap 0V, positive-QTOF | splash10-0002-0900000000-8f691ae372d6f1d18226 | 2020-07-22 | HMDB team, MONA | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - 4-Hydroxybutyric acid 10V, Positive-QTOF | splash10-000i-9100000000-80636ab7e3cb47d4d58f | 2015-09-15 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - 4-Hydroxybutyric acid 20V, Positive-QTOF | splash10-05n4-9000000000-71899633e269029ab7f9 | 2015-09-15 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - 4-Hydroxybutyric acid 40V, Positive-QTOF | splash10-0006-9000000000-910235f5bc92bcca7469 | 2015-09-15 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - 4-Hydroxybutyric acid 10V, Negative-QTOF | splash10-0udi-8900000000-5890f0a527dd16d9ac75 | 2015-09-15 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - 4-Hydroxybutyric acid 20V, Negative-QTOF | splash10-0k9i-9200000000-241210fedf9304168090 | 2015-09-15 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - 4-Hydroxybutyric acid 40V, Negative-QTOF | splash10-0a4l-9000000000-21d09118dfcfcb093f8d | 2015-09-15 | Wishart Lab | View Spectrum |
NMR SpectraSpectrum Type | Description | Deposition Date | Source | View |
---|
Predicted 1D NMR | 13C NMR Spectrum (1D, 100 MHz, H2O, predicted) | 2022-08-18 | Wishart Lab | View Spectrum | Predicted 1D NMR | 1H NMR Spectrum (1D, 100 MHz, H2O, predicted) | 2022-08-18 | Wishart Lab | View Spectrum | Predicted 1D NMR | 13C NMR Spectrum (1D, 1000 MHz, H2O, predicted) | 2022-08-18 | Wishart Lab | View Spectrum | Predicted 1D NMR | 1H NMR Spectrum (1D, 1000 MHz, H2O, predicted) | 2022-08-18 | Wishart Lab | View Spectrum | Predicted 1D NMR | 13C NMR Spectrum (1D, 200 MHz, H2O, predicted) | 2022-08-18 | Wishart Lab | View Spectrum | Predicted 1D NMR | 1H NMR Spectrum (1D, 200 MHz, H2O, predicted) | 2022-08-18 | Wishart Lab | View Spectrum | Predicted 1D NMR | 13C NMR Spectrum (1D, 300 MHz, H2O, predicted) | 2022-08-18 | Wishart Lab | View Spectrum | Predicted 1D NMR | 1H NMR Spectrum (1D, 300 MHz, H2O, predicted) | 2022-08-18 | Wishart Lab | View Spectrum | Predicted 1D NMR | 13C NMR Spectrum (1D, 400 MHz, H2O, predicted) | 2022-08-18 | Wishart Lab | View Spectrum | Predicted 1D NMR | 1H NMR Spectrum (1D, 400 MHz, H2O, predicted) | 2022-08-18 | Wishart Lab | View Spectrum | Predicted 1D NMR | 13C NMR Spectrum (1D, 500 MHz, H2O, predicted) | 2022-08-18 | Wishart Lab | View Spectrum | Predicted 1D NMR | 1H NMR Spectrum (1D, 500 MHz, H2O, predicted) | 2022-08-18 | Wishart Lab | View Spectrum | Predicted 1D NMR | 13C NMR Spectrum (1D, 600 MHz, H2O, predicted) | 2022-08-18 | Wishart Lab | View Spectrum | Predicted 1D NMR | 1H NMR Spectrum (1D, 600 MHz, H2O, predicted) | 2022-08-18 | Wishart Lab | View Spectrum | Predicted 1D NMR | 13C NMR Spectrum (1D, 700 MHz, H2O, predicted) | 2022-08-18 | Wishart Lab | View Spectrum | Predicted 1D NMR | 1H NMR Spectrum (1D, 700 MHz, H2O, predicted) | 2022-08-18 | Wishart Lab | View Spectrum | Predicted 1D NMR | 13C NMR Spectrum (1D, 800 MHz, H2O, predicted) | 2022-08-18 | Wishart Lab | View Spectrum | Predicted 1D NMR | 1H NMR Spectrum (1D, 800 MHz, H2O, predicted) | 2022-08-18 | Wishart Lab | View Spectrum | Predicted 1D NMR | 13C NMR Spectrum (1D, 900 MHz, H2O, predicted) | 2022-08-18 | Wishart Lab | View Spectrum | Predicted 1D NMR | 1H NMR Spectrum (1D, 900 MHz, H2O, predicted) | 2022-08-18 | Wishart Lab | View Spectrum |
IR SpectraSpectrum Type | Description | Deposition Date | Source | View |
---|
Predicted IR Spectrum | IR Ion Spectrum (Predicted IRIS Spectrum, Adduct: [M-H]-) | 2023-02-03 | FELIX lab | View Spectrum | Predicted IR Spectrum | IR Ion Spectrum (Predicted IRIS Spectrum, Adduct: [M+H]+) | 2023-02-03 | FELIX lab | View Spectrum | Predicted IR Spectrum | IR Ion Spectrum (Predicted IRIS Spectrum, Adduct: [M+Na]+) | 2023-02-03 | FELIX lab | View Spectrum |
|
---|
Biological Properties |
---|
Cellular Locations | Not Available |
---|
Biospecimen Locations | - Blood
- Cerebrospinal Fluid (CSF)
- Feces
- Saliva
- Urine
|
---|
Tissue Locations | |
---|
Pathways | |
---|
Normal Concentrations |
---|
| |
Blood | Detected and Quantified | 1.200 +/- 1.2(0-3.2) uM | Infant (0-1 year old) | Both | Normal | | details | Blood | Detected and Quantified | 48.0 (0.0-96.0) uM | Adult (>18 years old) | Both | Normal | | details | Cerebrospinal Fluid (CSF) | Detected and Quantified | <2.600 uM | Children (1 - 13 years old) | Not Specified | Normal | | details | Cerebrospinal Fluid (CSF) | Detected and Quantified | 0.98 +/- 1.17 uM | Adult (>18 years old) | Both | Normal | | details | Feces | Detected but not Quantified | Not Quantified | Adult (>18 years old) | Both | Normal | | details | Saliva | Detected but not Quantified | Not Quantified | Adult (>18 years old) | Both | Normal | | details | Saliva | Detected but not Quantified | Not Quantified | Adult (>18 years old) | Male | Normal | | details | Saliva | Detected but not Quantified | Not Quantified | Adult (>18 years old) | Male | Normal | | details | Saliva | Detected but not Quantified | Not Quantified | Adult (>18 years old) | Male | Normal | | details | Saliva | Detected but not Quantified | Not Quantified | Adult (>18 years old) | Male | Normal | | details | Saliva | Detected but not Quantified | Not Quantified | Adult (>18 years old) | Male | Normal | | details | Saliva | Detected but not Quantified | Not Quantified | Adult (>18 years old) | Male | Normal | | details | Saliva | Detected but not Quantified | Not Quantified | Adult (>18 years old) | Male | Normal | | details | Saliva | Detected but not Quantified | Not Quantified | Adult (>18 years old) | Male | Normal | | details | Saliva | Detected but not Quantified | Not Quantified | Adult (>18 years old) | Male | Normal | | details | Saliva | Detected but not Quantified | Not Quantified | Adult (>18 years old) | Male | Normal | | details | Urine | Detected and Quantified | 7.2 (2.7-22.3) umol/mmol creatinine | Adult (>18 years old) | Both | Normal | | details | Urine | Detected and Quantified | 1.8-2.9 umol/mmol creatinine | Adult (>18 years old) | Female | Normal | | details | Urine | Detected and Quantified | 3.3 (0.0-10.8) umol/mmol creatinine | Not Specified | Not Specified | Normal | | details | Urine | Detected and Quantified | 20.002 +/- 7.257 umol/mmol creatinine | Children (1 - 13 years old) | Not Specified | Normal | | details | Urine | Detected and Quantified | 1.6 (0.3-5.8) umol/mmol creatinine | Adult (>18 years old) | Both | Normal | | details | Urine | Detected and Quantified | 0.0 umol/mmol creatinine | Children (1 - 18 years old) | Both | Normal | | details | Urine | Detected and Quantified | 1.6-2.0 umol/mmol creatinine | Adult (>18 years old) | Male | Normal | | details | Urine | Detected and Quantified | 0.4 (0.0-1.9) umol/mmol creatinine | Adult (>18 years old) | Both | Normal | | details | Urine | Detected and Quantified | 0.37 (0.0-0.9) umol/mmol creatinine | Adult (>18 years old) | Female | Normal | | details | Urine | Detected and Quantified | 3.300 +/- 3.300 umol/mmol creatinine | Infant (0-1 year old) | Both | Normal | | details |
|
---|
Abnormal Concentrations |
---|
| |
Blood | Detected and Quantified | 2110-2920 uM | Infant (0-1 year old) | Male | Succinic semialdehyde dehydrogenase deficiency | | details | Cerebrospinal Fluid (CSF) | Detected and Quantified | 17 - 594 uM | Children (1-13 years old) | Not Specified | Succinic semialdehyde dehydrogenase deficiency | | details | Cerebrospinal Fluid (CSF) | Detected and Quantified | 1760-2200 uM | Infant (0-1 year old) | Male | Succinic semialdehyde dehydrogenase deficiency | | details | Feces | Detected but not Quantified | Not Quantified | Adult (>18 years old) | Both | Colorectal cancer | | details | Feces | Detected but not Quantified | Not Quantified | Adult (>18 years old) | Both | Colorectal Cancer | | details | Feces | Detected but not Quantified | Not Quantified | Adult (>18 years old) | Both | Colorectal cancer | | details | Saliva | Detected but not Quantified | Not Quantified | Adult (>18 years old) | Male | Attachment loss | | details | Saliva | Detected but not Quantified | Not Quantified | Adult (>18 years old) | Male | Missing teeth | | details | Saliva | Detected but not Quantified | Not Quantified | Adult (>18 years old) | Male | Periodontal Probing Depth | | details | Saliva | Detected but not Quantified | Not Quantified | Adult (>18 years old) | Male | Tooth Decay | | details | Urine | Detected and Quantified | 17.277 +/- 19.542 umol/mmol creatinine | Children (1 - 13 years old) | Not Specified | Eosinophilic esophagitis | | details | Urine | Detected and Quantified | 1.00 (0.00-2.00) umol/mmol creatinine | Adult (>18 years old) | Both | Glutaric aciduria II | | details | Urine | Detected and Quantified | 3865.0 (130.00-7600.00) umol/mmol creatinine | Children (1-13 years old) | Both | Glutaric Aciduria II | | details | Urine | Detected but not Quantified | Not Quantified | Adult (>18 years old) | Both | Bladder cancer | | details | Urine | Detected and Quantified | 880-3630 umol/mmol creatinine | Infant (0-1 year old) | Male | Succinic semialdehyde dehydrogenase deficiency | | details |
|
---|
Associated Disorders and Diseases |
---|
Disease References | Succinic semialdehyde dehydrogenase deficiency |
---|
- Ergezinger K, Jeschke R, Frauendienst-Egger G, Korall H, Gibson KM, Schuster VH: Monitoring of 4-hydroxybutyric acid levels in body fluids during vigabatrin treatment in succinic semialdehyde dehydrogenase deficiency. Ann Neurol. 2003 Nov;54(5):686-9. [PubMed:14595661 ]
- Shinka T, Inoue Y, Ohse M, Ito A, Ohfu M, Hirose S, Kuhara T: Rapid and sensitive detection of urinary 4-hydroxybutyric acid and its related compounds by gas chromatography-mass spectrometry in a patient with succinic semialdehyde dehydrogenase deficiency. J Chromatogr B Analyt Technol Biomed Life Sci. 2002 Aug 25;776(1):57-63. [PubMed:12127325 ]
| Colorectal cancer |
---|
- Brown DG, Rao S, Weir TL, O'Malia J, Bazan M, Brown RJ, Ryan EP: Metabolomics and metabolic pathway networks from human colorectal cancers, adjacent mucosa, and stool. Cancer Metab. 2016 Jun 6;4:11. doi: 10.1186/s40170-016-0151-y. eCollection 2016. [PubMed:27275383 ]
- Sinha R, Ahn J, Sampson JN, Shi J, Yu G, Xiong X, Hayes RB, Goedert JJ: Fecal Microbiota, Fecal Metabolome, and Colorectal Cancer Interrelations. PLoS One. 2016 Mar 25;11(3):e0152126. doi: 10.1371/journal.pone.0152126. eCollection 2016. [PubMed:27015276 ]
- Goedert JJ, Sampson JN, Moore SC, Xiao Q, Xiong X, Hayes RB, Ahn J, Shi J, Sinha R: Fecal metabolomics: assay performance and association with colorectal cancer. Carcinogenesis. 2014 Sep;35(9):2089-96. doi: 10.1093/carcin/bgu131. Epub 2014 Jul 18. [PubMed:25037050 ]
| Attachment loss |
---|
- Liebsch C, Pitchika V, Pink C, Samietz S, Kastenmuller G, Artati A, Suhre K, Adamski J, Nauck M, Volzke H, Friedrich N, Kocher T, Holtfreter B, Pietzner M: The Saliva Metabolome in Association to Oral Health Status. J Dent Res. 2019 Jun;98(6):642-651. doi: 10.1177/0022034519842853. Epub 2019 Apr 26. [PubMed:31026179 ]
| Missing teeth |
---|
- Liebsch C, Pitchika V, Pink C, Samietz S, Kastenmuller G, Artati A, Suhre K, Adamski J, Nauck M, Volzke H, Friedrich N, Kocher T, Holtfreter B, Pietzner M: The Saliva Metabolome in Association to Oral Health Status. J Dent Res. 2019 Jun;98(6):642-651. doi: 10.1177/0022034519842853. Epub 2019 Apr 26. [PubMed:31026179 ]
| Periodontal Probing Depth |
---|
- Liebsch C, Pitchika V, Pink C, Samietz S, Kastenmuller G, Artati A, Suhre K, Adamski J, Nauck M, Volzke H, Friedrich N, Kocher T, Holtfreter B, Pietzner M: The Saliva Metabolome in Association to Oral Health Status. J Dent Res. 2019 Jun;98(6):642-651. doi: 10.1177/0022034519842853. Epub 2019 Apr 26. [PubMed:31026179 ]
| Tooth Decay |
---|
- Liebsch C, Pitchika V, Pink C, Samietz S, Kastenmuller G, Artati A, Suhre K, Adamski J, Nauck M, Volzke H, Friedrich N, Kocher T, Holtfreter B, Pietzner M: The Saliva Metabolome in Association to Oral Health Status. J Dent Res. 2019 Jun;98(6):642-651. doi: 10.1177/0022034519842853. Epub 2019 Apr 26. [PubMed:31026179 ]
| Glutaric aciduria II |
---|
- G.Frauendienst-Egger, Friedrich K. Trefz (2017). MetaGene: Metabolic & Genetic Information Center (MIC: http://www.metagene.de). METAGENE consortium.
| Eosinophilic esophagitis |
---|
- Slae, M., Huynh, H., Wishart, D.S. (2014). Analysis of 30 normal pediatric urine samples via NMR spectroscopy (unpublished work). NA.
|
|
---|
Associated OMIM IDs | - 271980 (Succinic semialdehyde dehydrogenase deficiency)
- 114500 (Colorectal cancer)
- 231680 (Glutaric aciduria II)
- 610247 (Eosinophilic esophagitis)
|
---|
External Links |
---|
DrugBank ID | Not Available |
---|
Phenol Explorer Compound ID | Not Available |
---|
FooDB ID | FDB022196 |
---|
KNApSAcK ID | Not Available |
---|
Chemspider ID | 9984 |
---|
KEGG Compound ID | C01991 |
---|
BioCyc ID | 4-HYDROXY-BUTYRATE |
---|
BiGG ID | Not Available |
---|
Wikipedia Link | Oxybate |
---|
METLIN ID | 5678 |
---|
PubChem Compound | 10413 |
---|
PDB ID | Not Available |
---|
ChEBI ID | 30830 |
---|
Food Biomarker Ontology | Not Available |
---|
VMH ID | 4HDXBUTN |
---|
MarkerDB ID | MDB00000230 |
---|
Good Scents ID | Not Available |
---|
References |
---|
Synthesis Reference | Takigawa, Shinichiro; Araya, Shuzo. Process for the preparation of g-hydroxybutyric acid as a synthetic intermediate. Jpn. Kokai Tokkyo Koho (1988), 3 pp. |
---|
Material Safety Data Sheet (MSDS) | Not Available |
---|
General References | - Brown GK, Cromby CH, Manning NJ, Pollitt RJ: Urinary organic acids in succinic semialdehyde dehydrogenase deficiency: evidence of alpha-oxidation of 4-hydroxybutyric acid, interaction of succinic semialdehyde with pyruvate dehydrogenase and possible secondary inhibition of mitochondrial beta-oxidation. J Inherit Metab Dis. 1987;10(4):367-75. [PubMed:3126356 ]
- Gibson KM, Baumann C, Ogier H, Rossier E, Vollmer B, Jakobs C: Pre- and postnatal diagnosis of succinic semialdehyde dehydrogenase deficiency using enzyme and metabolite assays. J Inherit Metab Dis. 1994;17(6):732-7. [PubMed:7707697 ]
- Gibson KM, Aramaki S, Sweetman L, Nyhan WL, DeVivo DC, Hodson AK, Jakobs C: Stable isotope dilution analysis of 4-hydroxybutyric acid: an accurate method for quantification in physiological fluids and the prenatal diagnosis of 4-hydroxybutyric aciduria. Biomed Environ Mass Spectrom. 1990 Feb;19(2):89-93. [PubMed:2407302 ]
- Shinka T, Inoue Y, Ohse M, Ito A, Ohfu M, Hirose S, Kuhara T: Rapid and sensitive detection of urinary 4-hydroxybutyric acid and its related compounds by gas chromatography-mass spectrometry in a patient with succinic semialdehyde dehydrogenase deficiency. J Chromatogr B Analyt Technol Biomed Life Sci. 2002 Aug 25;776(1):57-63. [PubMed:12127325 ]
- Ergezinger K, Jeschke R, Frauendienst-Egger G, Korall H, Gibson KM, Schuster VH: Monitoring of 4-hydroxybutyric acid levels in body fluids during vigabatrin treatment in succinic semialdehyde dehydrogenase deficiency. Ann Neurol. 2003 Nov;54(5):686-9. [PubMed:14595661 ]
- LeBeau MA, Montgomery MA, Morris-Kukoski C, Schaff JE, Deakin A, Levine B: A comprehensive study on the variations in urinary concentrations of endogenous gamma-hydroxybutyrate (GHB). J Anal Toxicol. 2006 Mar;30(2):98-105. [PubMed:16620539 ]
- Kankaanpaa A, Liukkonen R, Ariniemi K: Determination of gamma-hydroxybutyrate (GHB) and its precursors in blood and urine samples: a salting-out approach. Forensic Sci Int. 2007 Aug 6;170(2-3):133-8. Epub 2007 Jul 20. [PubMed:17658710 ]
- Hedner T, Hedner J, Iversen K, Wessberg P, Lundborg P: Gammahydroxybutyric acid: central biochemical and behavioral effects in neonatal rats. Pharmacol Biochem Behav. 1985 Aug;23(2):185-9. [PubMed:2997806 ]
- van Amsterdam JG, Brunt TM, McMaster MT, Niesink R, van Noorden MS, van den Brink W: [Cognitive impairment due to intensive use and overdoses of gammahydroxybutyric acid (GHB)]. Tijdschr Psychiatr. 2012;54(12):1001-10. [PubMed:23250641 ]
- Stock G, Heidt H, Buss J, Schlor KH: Sleep patterns in cat induced by gammahydroxybutyric acid. Electroencephalogr Clin Neurophysiol. 1978 Apr;44(4):523-7. [PubMed:76561 ]
- Anden NE, Stock G: Inhibitory effect of gammahydroxybutyric acid and gammaaminobutyric acid on the dopamine cells in the substantia nigra. Naunyn Schmiedebergs Arch Pharmacol. 1973;279(1):89-92. [PubMed:4356204 ]
- Gomes C, Flygt C, Henning M, Norin L, Svensson TH, Trolin G: Gammahydroxy butyric acid: cardiovascular effects in the rat. J Neural Transm. 1976;38(2):123-9. [PubMed:1271050 ]
- Pedraza C, Garcia FB, Navarro JF: Neurotoxic effects induced by gammahydroxybutyric acid (GHB) in male rats. Int J Neuropsychopharmacol. 2009 Oct;12(9):1165-77. doi: 10.1017/S1461145709000157. Epub 2009 Mar 17. [PubMed:19288974 ]
- Hedner T, Lundborg P: Effect of gammahydroxybutyric acid on catecholamine synthesis and utilization in the developing rat brain. J Neural Transm. 1982;54(1-2):19-28. [PubMed:6809892 ]
- Hedner T, Lundborg P: Effect of gammahydroxybutyric acid on serotonin synthesis, concentration and metabolism in the developing rat brain. J Neural Transm. 1983;57(1-2):39-48. [PubMed:6194255 ]
- Johansson B, Hardebo JE: Cerebrovascular permeability and cerebral blood flow in hypertension induced by gammahydroxybutyric acid. An experimental study in the rat. Acta Neurol Scand. 1982 May;65(5):448-57. [PubMed:7113657 ]
- Hedner T, Lundborg P: Neurochemical characteristics of cerebral catecholamine neurons during the postnatal development in the rat. Med Biol. 1981 Aug;59(4):212-23. [PubMed:6803074 ]
- Giorgi O, Rubio MC: Decreased 3H-L-quinuclidinyl benzilate binding and muscarine receptor subsensitivity after chronic gamma-butyrolactone treatment. Naunyn Schmiedebergs Arch Pharmacol. 1981 Dec;318(1):14-8. [PubMed:7329448 ]
- Anden NE, Wachtel H: Biochemical effects of baclofen (beta-parachlorophenyl-GABA) on the dopamine and the noradrenaline in the rat brain. Acta Pharmacol Toxicol (Copenh). 1977 Feb;40(2):310-20. [PubMed:576560 ]
- Stock G: Failure of anticholinergic drugs to antagonize the increase in dopamine seen after gammahydroxybutyric acid and axotomy. J Neural Transm. 1979;44(1-2):137-43. [PubMed:438801 ]
- Baumann KW, Kassell NF, Olin J, Yamada T: The effects of gammahydroxybutyric acid on canine cerebral blood flow and metabolism. J Neurosurg. 1982 Aug;57(2):197-202. [PubMed:7086512 ]
- Stock G, Magnusson T, Anden NE: Increase in brain dopamine after axotomy or treatment with gammahydroxybutyric acid due to elimination of the nerve impulse flow. Naunyn Schmiedebergs Arch Pharmacol. 1973;278(4):347-61. [PubMed:4269968 ]
- Vulliemoz S, Vanini G, Truffert A, Chizzolini C, Seeck M: Epilepsy and cerebellar ataxia associated with anti-glutamic acid decarboxylase antibodies. J Neurol Neurosurg Psychiatry. 2007 Feb;78(2):187-9. [PubMed:17229747 ]
- Gessa GL: [Guidelines for the drug therapy of alcoholism]. Recenti Prog Med. 1990 Mar;81(3):171-5. [PubMed:2359869 ]
- Anden NE, Magnusson T, Stock G: Effects of drugs influencing monoamine mechanisms on the increase in brain dopamine produced by axotomy or treatment with gammahydroxybutyric acid. Naunyn Schmiedebergs Arch Pharmacol. 1973;278(4):363-72. [PubMed:4269969 ]
- Simons K, Toomre D: Lipid rafts and signal transduction. Nat Rev Mol Cell Biol. 2000 Oct;1(1):31-9. [PubMed:11413487 ]
- Watson AD: Thematic review series: systems biology approaches to metabolic and cardiovascular disorders. Lipidomics: a global approach to lipid analysis in biological systems. J Lipid Res. 2006 Oct;47(10):2101-11. Epub 2006 Aug 10. [PubMed:16902246 ]
- Sethi JK, Vidal-Puig AJ: Thematic review series: adipocyte biology. Adipose tissue function and plasticity orchestrate nutritional adaptation. J Lipid Res. 2007 Jun;48(6):1253-62. Epub 2007 Mar 20. [PubMed:17374880 ]
- Lingwood D, Simons K: Lipid rafts as a membrane-organizing principle. Science. 2010 Jan 1;327(5961):46-50. doi: 10.1126/science.1174621. [PubMed:20044567 ]
- Zhang L, Shi ZY, Wu Q, Chen GQ: Microbial production of 4-hydroxybutyrate, poly-4-hydroxybutyrate, and poly(3-hydroxybutyrate-co-4-hydroxybutyrate) by recombinant microorganisms. Appl Microbiol Biotechnol. 2009 Oct;84(5):909-16. doi: 10.1007/s00253-009-2023-7. Epub 2009 May 12. [PubMed:19434404 ]
- Elshenawy S, Pinney SE, Stuart T, Doulias PT, Zura G, Parry S, Elovitz MA, Bennett MJ, Bansal A, Strauss JF 3rd, Ischiropoulos H, Simmons RA: The Metabolomic Signature of the Placenta in Spontaneous Preterm Birth. Int J Mol Sci. 2020 Feb 4;21(3). pii: ijms21031043. doi: 10.3390/ijms21031043. [PubMed:32033212 ]
- Gunstone, Frank D., John L. Harwood, and Albert J. Dijkstra (2007). The lipid handbook with CD-ROM. CRC Press.
|
---|